Immuno-oncology biotech Five Prime has outlicensed a medication from its protein discovery platform exclusively to Belgium biopharma UCB.

The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.

Norbert Bischofberger is stepping down as Gilead's EVP of R&D and chief scientific officer, as the company promotes John McHutchison to the top job.

Anthera has cut loose its failed late-stage Lilly castoff Sollpura as it seeks “strategic alternatives.”

As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.

Pfizer is backing out of its $635 million armed antibody tech deal with CytomX.

A CAR-T biotech formed by Juno and WuXi got off a $90 million series A with Chinese backing, as it eyes clinical trials of its new cancer therapy.

Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.